SBC Medical Group (SBC) vs GeneDx (WGS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
SBC Medical Group (SBC) has outperformed GeneDx (WGS) over the past year, gaining 56.2% versus a loss of 69.0%. GeneDx is the larger company by market cap ($1.36 billion vs $530.3 million), about 2.6 times the size. On valuation, SBC Medical Group trades at a lower forward P/E (9.0x vs 34.9x for GeneDx).
SBC Medical Group converts more of its revenue into profit, with a net margin of 29.4% versus -4.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SBC | WGS |
|---|---|---|
| Share price | $5.17 | $45.46 |
| Market cap | $530.32M | $1.36B |
| 1-day change | -7.68% | -7.68% |
| YTD return | +19.95% | -65.05% |
| 1-year return | +56.19% | -68.98% |
| 5-year return | — | -80.01% |
| P/E ratio (TTM) | 10.14 | — |
| Forward P/E | 8.99 | 34.93 |
| EPS (TTM) | $0.51 | $-3.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $173.61M | $427.54M |
| Revenue growth (YoY) | -15.48% | +39.97% |
| Net income (latest FY) | $50.99M | $-21.02M |
| Gross margin | 73.32% | 69.74% |
| Operating margin | 38.87% | -3.06% |
| Net margin | 29.37% | -4.92% |
| 52-week high | $7.39 | $170.87 |
| 52-week low | $2.78 | $32.21 |
| Distance from 52-week high | -30.04% | -73.39% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +93.42% | +80.38% |
| Average volume | 256.99K | 869.34K |
| Shares outstanding | 102.58M | 29.97M |
| Employees | 863 | 1,300 |
| Sector | Health Care | Health Care |
| Industry | Medical/Nursing Services | Medical/Nursing Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GeneDx is about 2.6 times larger than SBC Medical Group by market value ($1.36B vs $530.32M).
- SBC has outperformed WGS by 125.2 percentage points over the past year.
- SBC Medical Group is more profitable, keeping 29.4 cents of every revenue dollar as net income versus -4.9 cents for GeneDx.
- GeneDx grew revenue faster in its latest fiscal year (+39.97% vs -15.48%).
About SBC Medical Group
SBC stock →SBC Medical Group Holdings Incorporated, together with its subsidiaries, provides management services to cosmetic treatment centers in Japan, Vietnam, the United States, and Singapore. The company offers advertising and marketing services across social media networks; staff management services, such as recruitment and training; booking reservations for franchisee clinic customers; assistance with franchisee employee housing rentals; leasehold improvement services; and design services for clinics, medical equipment, and medical consumables procurement.
Health Care · Medical/Nursing Services · 863 employees
About GeneDx
WGS stock →GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.
Health Care · Medical/Nursing Services · 1,300 employees
SBC vs WGS FAQ
Which is bigger, SBC Medical Group or GeneDx?
GeneDx (WGS) is larger, with a market capitalization of $1.36B compared with $530.32M for SBC Medical Group (SBC).
Which stock has performed better over the past year, SBC or WGS?
SBC returned +56.19% over the past 12 months, compared with -68.98% for WGS (price return, excluding dividends). Past performance does not predict future results.
Are SBC Medical Group and GeneDx in the same industry?
Yes. Both are classified in the Medical/Nursing Services industry within the Health Care sector.